Evidence map›Paper›PMID 27404213›Full record

ArticleAnnals of the American Thoracic Society2016

Epidemiology of Vasopressin Use for Adults with Septic Shock.

Emily A Vail, Hayley B Gershengorn, May Hua, Allan J Walkey, Hannah Wunsch

Abstract readMulticenter Study
In one paragraph

Article in Annals of the American Thoracic Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Timing of Vasopressin Initiation in Patients with Septic Shock: An Updated Systematic Review and Meta-analysis with Trial Sequential Analysis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025
    Article
  11. Observational
  12. Article
  13. Review
  14. Timing of adjunctive vasopressin initiation for septic shock patients and hospital mortality: A multicentre observational study.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2024
    Article
  15. Review
  16. Article
  17. Adoption of a Novel Vasopressor Agent in Critically Ill Adults.Annals of the American Thoracic Society · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Emily A Vail1 Department of Anesthesiology, Columbia University, New York, New York.ORCID 0000-0002-1849-5780
Hayley B Gershengorn2 Department of Medicine, and.
May Hua1 Department of Anesthesiology, Columbia University, New York, New York.
Allan J Walkey5 Boston University Department of Medicine, Boston, Massachusetts.
Hannah Wunsch6 University of Toronto Department of Anesthesiology, Toronto, Ontario, Canada; and.

Funding

Determinants of Critical Care Intensity for Hospitalized Older Adults: the Effect of Hospital-based Palliative Care ServicesK08AG051184 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HUA, MAY · 2015 to 2019
$863k
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice PatternsK01HL116768 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WALKEY, ALLAN J. · 2013 to 2017
$742k
NHLBI NIH HHS K01 HL116768NIA NIH HHS K08 AG051184NIA NIH HHS L30 AG053861
6 · The paper itself

Abstract

rationaleVasopressin may be used to treat vasodilatory hypotension in septic shock, but it is not recommended by guidelines as a first- or second-line agent. Little is known about how often the drug is used currently in septic shock.

objectivesWe conducted this study to describe patterns of vasopressin use in a large cohort of U.S. adults with septic shock and to identify patient and hospital characteristics associated with vasopressin use.

methodsThis was a retrospective cohort study of adults admitted to U.S. hospitals with septic shock in the Premier healthcare database (July 2008 to June 2013). We performed multilevel mixed-effects logistic regression with hospitals as a random effect to identify factors associated with use of vasopressin alone or in combination with other vasopressors on at least 1 day of hospital admission. We calculated quotients of Akaike Information Criteria (AIC) to determine relative contributions of patient and hospital characteristics to observed variation. MEASUREMENTS AND MAIN

resultsAmong 584,421 patients with septic shock in 532 hospitals, 100,923 (17.2%) received vasopressin. A total of 6.1% of patients receiving vasopressin received vasopressin alone, and 93.9% received vasopressin in combination with other vasopressors (up to five vasopressors in 15 different combinations). The mean monthly rate of vasopressin use increased from 14.5 to 19.6% over the study period, representing an average annual relative increase of 8% (P < 0.001). The median hospital rate of vasopressin use for septic shock was 11.7% (range, 0-69.7%). Patient demographic and clinical characteristics, including patient age (adjusted odds ratio, 0.71 for age > 85 yr compared with the reference group of age < 50 yr; 95% confidence interval, 0.69-0.74) and acute respiratory dysfunction (adjusted odds ratio, 3.25; 95% confidence interval, 3.20-3.31), were responsible for the majority of observed variation in vasopressin use (quotient of AICs, 0.56). However, hospital of admission also contributed substantially to observed variation (quotient of AICs, 0.37).

conclusionsApproximately one-fifth of patients with septic shock received vasopressin, but rarely as a single vasopressor. The use of vasopressin has increased over time. The likelihood of receiving vasopressin was strongly associated with the specific hospital to which each patient was admitted.

Indexed as

AgedDatabases, FactualDrug Therapy, CombinationDrug UtilizationFemaleHospitalsHumansHypotensionLogistic ModelsMaleMiddle AgedOdds RatioRetrospective StudiesShock, SepticUnited StatesVasoconstrictor AgentsVasoconstrictor AgentsVasopressinspractice variationseptic shockvasoconstrictor agents

Identifiers

PMID27404213
PMCPMC5122493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.